From: Genetic and molecular biology of systemic lupus erythematosus among Iranian patients: an overview
Study (et al.) | Year | Gene | Population | Results |
---|---|---|---|---|
Tahmasebi [36] | 2013 | IL-1RN | 213 NCa 207 SLEb | Polymorphism was correlated with SLE progression |
Mahmoudi [42] | 2014 | IL-4 | 140 NC 59 SLE | Polymorphism was correlated with SLE progression |
Mohammadi [47] | 2019 | IL-10 | 131 NC 116 SLE | Polymorphism was correlated with SLE progression |
Mirkazemi [58] | 2013 | STAT4 | 281 NC 280 SLE | Polymorphism was correlated with SLE progression |
Alesaeidi [76] | 2015 | MECP2 | 392 NC 492 SLE | Polymorphism was correlated with SLE progression |
Sahebari [79] | 2010 | FAS | 50 NC 114 SLE | Different serum levels of Fas between cases and controls |
Moudi [82] | 2013 | FAS, FASL | 149 NC 106 SLE | Polymorphism was correlated with SLE progression |
Araste [86] | 2010 | FAS | 249 NC 212 SLE | Polymorphism was correlated with SLE progression |
Fathi [90] | 2020 | PDCD1 | 564 NC 253 SLE | Polymorphism was correlated with SLE progression |
Mahmoudi [91] | 2015 | PDCD1 | 50 NC 202 SLE | Polymorphism was correlated with SLE progression |
Rajabi [102] | 2012 | TNFSF4, TRAF2 | 57 NC 57 SLE | Increased and decreased levels of TNFSF4 and TRAF2 expressions respectively |
Namazi [107] | 2017 | APRIL | 64 NC 60 SLE | Increased serum APRIL levels |
Salimi [110] | 2018 | ERa | 186 NC 170 SLE | Polymorphism was correlated with SLE progression |
Shojaa [114] | 2017 | CTLA‐4 | 304 NC 180 SLE | Polymorphism was correlated with SLE progression |
Salimi [118] | 2014 | XRCC1 | 180 NC 163 SLE | Polymorphism was correlated with SLE progression |
Jahantigh [122] | 2015 | XRCC5, XRCC7 | 180 NC 163 SLE | Polymorphism was correlated with SLE progression |
Salimi [131] | 2016 | Osteopontin | 180 NC 163 SLE | Polymorphism was correlated with SLE progression |
Mirfeizi [135] | 2012 | UMCP-1 | 67 SLE | Increased UMCP-1 levels |
Noroozinia [143] | 2016 | CD34 | 73 SLE | CD34 expression was associated with activity index |
Sharifipour [147] | 2013 | LCN2 | 52 SLE | Increased urinary LCN2/creatinine level |
Bahrehmand [156] | 2012 | MMP-2 | 101 NC 109 SLE | Polymorphism was correlated with SLE progression |
Bahrami [175] | 2020 | PTPN22 | 93 NC 55 SLE | Polymorphism was correlated with SLE progression |
Sandoughi [185] | 2016 | eNOS | 194 NC 106 SLE | Polymorphism was correlated with SLE progression |
Bahrehmand [197] | 2013 | PON1 | 83 NC 109 SLE | Polymorphism was correlated with SLE progression |
Tanhapour [199] | 2018 | ApoE, PON1 | 117 NC 101 SLE | Polymorphism was correlated with SLE progression |
Khoshmirsafa [203] | 2019 | miR-16, miR-21, and miR-155 | 30 NC 55 SLE | Increased expression of miR-16, miR-21, and miR-155 while miR‐141 down regulation |
Vahed [206] | 2018 | miR-125a, miR-142-3p, miR-146a | 26 NC 26 SLE | Increased circulating miR-125a and miR-146a levels while reduced level of circulating miR-142-3p |
Nakhjavani [209] | 2019 | miR-21, miR-150, miR-423 | 26 NC 26 SLE | Reduced levels of circulating miR-150 while increased levels of circulating miR-21 and miR-423 |
Akhtari [214] | 2016 | KIR, HLA | 273 NC 230 SLE | Polymorphism was correlated with SLE progression |
Rezaieyazdi [215] | 2008 | HLA | 83 NC 40 SLE | Polymorphism was correlated with SLE progression |